Ribolife-B 06938
IPOIPO Allotment Results Analysis
43.0004.19%( -1.880 )
Nov 13 · End-of-day data, not live · Hong Kong Stock Exchange
Allotment Results · 20260109
IPOIPO Allotment Results Analysis| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| Bright Stone | 536,800 | 2.00% | 0.30% | 6 months |
| 华夏基金 | 2,013,200 | 7.30% | 1.20% | 6 months |
| 大成国际及大成基金(3) | 2,013,200 | 7.30% | 1.20% | 6 months |
| Erik Selin Fastigheter AB | 1,342,000 | 4.90% | 0.80% | 6 months |
| Himension Fund | 1,342,000 | 4.90% | 0.80% | 6 months |
| IvyRock | 536,800 | 2.00% | 0.30% | 6 months |
| Mingxin Growth Ventures | 1,342,000 | 4.90% | 0.80% | 6 months |
| Springs Capital(Hong Kong) | 1,342,000 | 4.90% | 0.80% | 6 months |
| 泰康人寿 | 1,610,400 | 5.10% | 1.00% | 6 months |
| 拾贝能信、自然拾贝及Huatai Capital Investment Limited | 671,000 | 2.40% | 0.40% | 6 months |
The IPO of 瑞博生物－Ｂ saw overwhelming retail demand with an oversubscription ratio of 101.06 times, resulting in a low hit rate of just 12.55%. This level of enthusiasm is typical for high-profile biotech listings under Chapter 18A, reflecting strong market appetite despite no clawback mechanism. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
The allocation at the top of the retail tier (甲尾) yielded an expected 0.2614 lots for an application of 80,000 lots, slightly higher than the 0.2275 lots expected for the bottom of the HKSFC tier (乙头) with 90,000 lots applied. This is unusual as B-head applicants typically receive a proportionally higher allocation, but here the marginal benefit of moving to the B tier is negligible, making the A-tail unexpectedly efficient relative to broker costs. (This is AI-generated commentary based on historical data. Broker fee structures vary and actual costs may differ. Not financial advice.)
No detailed demographic breakdown was available in the filing, with reported mainland and Hong Kong participant percentages at zero, likely indicating that the data was not disclosed or not applicable. In practice, biotech IPOs often draw significant interest from mainland Chinese investors despite Hong Kong-centric subscription channels. (This is AI-generated commentary based on historical data. Data may contain errors or omissions from source documents. Verify against official HKEX filings. Not financial advice.)
This page shows allotment analysis for Ribolife-B (06938): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.
